Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 12.5%Low 4 · 50%Moderate 3 · 37.5%High 0 · 0%

Adverse events · Adult patients with active ulcerative colitis

It is very uncertain whether budesonide MMX® 6 mg changes adverse events compared with placebo (very low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.13 [0.97, 1.32]
2 studies · 512 participants
Very low

Serious adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 6 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.63 [0.21, 1.91]
2 studies · 512 participants
Low

Withdrawals due to adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 6 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.1 [0.55, 2.22]
2 studies · 512 participants
Low

Adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in adverse events compared with entocort EC 9mg (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.01 [0.81, 1.26]
1 study · 254 participants
Moderate

Adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 1.09 [0.95, 1.26]
3 studies · 971 participants
Moderate

Serious adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with entocort EC 9mg (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 3.94 [0.45, 34.74]
1 study · 254 participants
Low

Serious adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.88 [0.33, 2.4]
2 studies · 513 participants
Low

Withdrawals due to adverse events · Adult patients with active ulcerative colitis

Budesonide MMX® 9 mg showed no clear difference in withdrawal due to adverse events compared with entocort EC 9mg (moderate certainty).

1 finding from 1 review

Oral budesonide for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
RR 0.94 [0.56, 1.58]
1 study · 254 participants
Moderate